Fiala

Peptide library › Heart & blood

Rusfertide

Also known as Mimrylo, PTG-300

FDA-approved drugHeart & blood

Weekly injection that mimics the iron hormone hepcidin to control red blood cell overproduction in polycythemia vera.

What people use it for

What Rusfertide does in the body

Mimics hepcidin, the body's master iron regulator. Limiting iron available to the bone marrow slows red blood cell production, reducing the need for blood removal (phlebotomy).

Strength of evidence

Strong: the Phase 3 VERIFY trial cut the need for phlebotomy versus placebo.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved on 28 August 2026 as Mimrylo, the first approved hepcidin mimetic. Prescription only.

How it's taken

Route: Injection under the skin, once weekly

How long it lasts (half-life): Long-acting; supports weekly dosing

Keep track of Rusfertide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Rusfertide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Heart & blood